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Case Report
Diabetic ketoacidosis associated with tacrolimus in
solid organ transplant recipients
Muhammad Qamar Masood,1 Madiha Rabbani,2 Wasim Jafri,3 Manal Habib,4 Taimur Saleem5
Section of Endocrinology, Department of Medicine,1 Medical Graduates of Class of 2009,2,4,5
Section of Gastroenterology, Department of Medicine,3 Aga Khan University, Karachi, Pakistan.

Abstract
Diabetic ketoacidosis in patients receiving
tacrolimus in the post-transplant setting is rare. We describe
two such cases in solid-organ transplant recipients. The first
patient, a 17-year-old male, presented with severe diabetic
ketoacidosis and was managed with intravenous fluids and
insulin infusion. He was a known case of Laurence-MoonBardet-Biedl syndrome and had received a renal transplant
2 years ago and was receiving tacrolimus since then.
Although diabetic ketoacidosis resolved in 24 hours, large
doses of subcutaneous insulin (upto 130 units per day) were
needed to keep serum glucose within the normal range.
Substitution of tacrolimus with cyclosporine obviated the
need for insulin or oral hypoglycaemics. The second patient,
a 55-year-old woman, presented with a history of polyuria
for 3 days. She had received a hepatic transplant 2 years ago
and tacrolimus was being used since then. Mild diabetic
ketoacidosis was managed with fluid resuscitation and
subcutaneous insulin. Her insulin requirement after an
uneventful recovery has been 54 - 70 units per day.
Clinicians should be cognizant of the possibility of
hyperglycaemic crisis presenting as sudden onset of diabetic
ketocidosis in patients receiving tacrolimus. Use of an
alternative calcineurin inhibitor may provide a safer
solution to minimize future morbidity in such patients.
Keywords: Tacrolimus, Post Transplantation Diabetes
mellitus, Diabetic ketocidosis, New onset Diabetes
Mellitus.

Introduction
Diabetic ketoacidosis (DKA) is a life-threatening
hyperglycaemic emergency in diabetic patients. Tacrolimus,
an immunomodulator also known as FK506, is a macrolide
antibiotic that has been used in the treatment of
inflammatory bowel disease (IBD), atopic dermatitis,
primary sclerosing cholangitis, autoimmune enteropathy as
well as for the prevention of allograft rejection in liver,
kidney and other solid organ transplant recipients.1
Tacrolimus has been associated with post-transplant
diabetes mellitus (PTDM). It inhibits the transcription of the
insulin gene in the beta-cell via inhibition of calcineurin
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after binding to FK506-binding protein 12 (FKBP12).2
However, despite this potential, the occurrence of
DKA in patients receiving tacrolimus in the post-transplant
setting is rare and only a few cases of this clinical
phenomenon have been reported in literature.3,4 We describe
two cases of DKA associated with tacrolimus treatment in
solid-organ transplant recipients.

Case History
Case-1:
A 17-year-old boy presented with a history of
polyuria, nocturia, dry mouth, and poor appetite intractable
vomiting, altered mentality and irritability for one day.
Although impaired fasting glucose (IFG) had been
documented on a few prior occasions, overt diabetes had
never been present. The patient was a known case of
Laurence-Moon-Bardet-Biedl syndrome. Deterioration in
kidney function was noted at the age of 12 years. This had
gradually progressed to end stage renal disease (ESRD)
leading to pre-emptive renal transplantation one year prior
to this presentation. He had been receiving
immunosuppressive treatment in the form of tacrolimus (6
mg bid), mycophenolate mofetil (1gram bid) and
prednisolone (5 mg qd) in the post-transplant setting.
Physical examination showed moderate to severe
dehydration and confusion without any overt focus of
infection. He was afebrile, had a heart rate of 140 beats per
minute, blood pressure of 126/70 mm Hg, respiratory rate of
30 per minute and oxygen saturation of 94% on room air.
His physical exam was significant for marked obesity,
acanthosis nigricans, vision limited to light perception only,
polydactyly and absence of secondary sexual
characteristics. His random blood glucose was 702 mg/dl
with large ketonuria and high anion gap metabolic acidosis
(pH-7.1, anion gap 25 mEq/l, serum bicarbonate 06 mEq/l).
The patient was managed with intravenous fluids, insulin
infusion and potassium replacement as per standard
protocols. Insulin infusion was discontinued within 24
hours with the normalization of arterial pH, serum anion
gap and disappearance of urine ketones. However, large
doses of subcutaneous insulin (up to 130 units per day) were
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still needed to keep serum glucose within normal range. In
view of extremely high daily insulin requirements,
tacrolimus was substituted with cyclosporine A. Following
this regime modification, his insulin requirements
significantly reduced (40 units per day). Complete insulin
independence was achieved within 2 weeks. At 2 years
follow-up, serum fasting plasma glucose (FPG) levels have
remained within normal range. Anti-GAD and islet cell
antibodies were both negative in this patient. Serum insulin
levels and C-peptide levels were, however, not checked.

Case-2:
A 55-year-old Pakistani woman presented with
complaints of dizziness and polyuria for 3 days. Her past
history was significant for hepatitis C virus (HCV) infection
(genotype 3a) 8 years ago. Although the infection was
successfully managed initially with interferon and ribavirin,
it relapsed after 2 years. Development of advanced cirrhosis
was associated with multiple episodes of decompensation
that necessitated hepatic transplantation from China 2 years
ago. She received immunosuppression in the post-transplant
setting in the form of mycophenolate mofetil and
tacrolimus. About 1 year after the transplant, she was still
PCR positive for HCV. She received another course of
interferon therapy and has been PCR negative since then.
She was started on prednisolone 40 mg about 5 weeks prior
to this episode for chronic rejection on liver biopsy done for
raised liver enzymes. She was self monitoring her blood
glucose at home; the measurements were within normal
range until one week prior to presentation. Physical
examination of the patient was remarkable for mild
dehydration. Her FPG was 404 mg/dl and random blood
glucose was 474 mg/dl with moderate ketonuria and mild
anion gap metabolic acidosis (anion gap 15 mmol/l, serum
bicarbonate of 16.4 mEq/l). Serum HbA1c level was 8.9%.
The patient was managed with fluid replacement and
subcutaneous insulin because of her stable condition.
Arterial pH and serum anion gap normalized shortly and
urine ketones disappeared within 12 hours. Her insulin
requirement after an uneventful recovery has been 54 - 70
units per day. Her most recent FPG was 118 mg/dl.
Although she is currently receiving tacrolimus and
prednisolone; substitution of tacrolimus with another agent
is under consideration.

Discussion
The diagnosis of drug induced diabetes mellitus
(DM) in our first patient presented a diagnostic dilemma
because of consideration for competing etiologies including
DM secondary to Laurence-Moon-Bardet-Biedl syndrome
and ketosis-prone type 2 DM. Laurence-Moon-BardetBiedl syndrome is an autosomal recessive condition
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characterized by rod-cone dystrophy, postaxial polydactyly,
central obesity, mental retardation, hypogonadism, and
renal dysfunction. In a large series of 109 patients, noninsulin dependent DM (NIDDM) was described in 6% of
the patients.5 In recent years, an increasing number of DKA
cases have also been reported in children, adolescents and
adults without any precipitating cause; these have been
referred to as atypical diabetes or ketosis-prone type 2 DM.
Increasing evidence indicates that this subtype of diabetes
accounts for more than half of newly diagnosed black and
Hispanic patients with DKA. These patients are usually
obese, have a strong family history of diabetes, have a low
prevalence of autoimmune markers, and lack a genetic
association with HLA.6 While our patient was obese and
had negative autoimmune markers, he also did not have a
family history of DM. A diagnosis of drug induced DM
leading to DKA is the most likely etiology in our patient
because of the rapid decline in insulin requirement and
insulin independence after withdrawal of tacrolimus.
Our second patient had received a hepatic transplant
secondary to HCV-induced cirrhosis. Although her infection
was active after the transplant, a course of interferon was
administered successfully and she had become PCR
negative. She was receiving tacrolimus for about 2 years;
and prednisolone was started 5 weeks before presentation,
her blood sugars were monitored at home and remained in
normal range on this dose for next 4 weeks, when she had
this episode of hyperglycaemia culminating in DKA. In a
large series comprising 21,489 primary transplant recipients
in the United States, it was seen that diabetic ketoacidosis
developed in 0.015% of the patients by 3 years posttransplant. Multivariate analysis showed that use of
tacrolimus as well as HCV infection increased the risk of
complications from new-onset DM (NODM) in these
patients including DKA.7
Although the mechanism by which tacrolimus
causes PTDM has been postulated, the reason why only
certain individuals develop DKA remains unknown. There
are only a handful of reports of DKA associated with
tacrolimus in the literature which makes risk stratification
for this rare clinical phenomenon an unfeasible task at the
moment. Documentation of more cases of similar nature is,
however, important.
In summary, use of tacrolimus may represent a
modifiable risk factor for non-insulin dependent DM or
its complications in solid organ transplant recipients.7
Although it is a highly effective immunosuppressive
agent in the post-transplant setting, the high incidence
of PTDM may prove counter-productive to its
prophylactic effect on allograft rejection.8 Studies have
shown that the diabetogenic potential of tacrolimus is
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higher than that of cyclosporine.9

Conclusion
Although rare, the sporadic reports of the incidence
of DKA complicating the course of PTDM in patients on
tacrolimus merit consideration while selecting an
immunosuppressive agent. Cyclosporine can be an effective
alternative in such situations. Also, while attention is largely
focused on the correction of metabolic and endocrine
derangements in the acute setting in a patient presenting
with DKA, clinicians should also be cognizant of the
importance of seeking an underlying etiology of the
disorder in order to prevent recurrent episodes in the future.
If drug-induced, discontinuation of the drug offers a simple
solution to minimize future morbidity.
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